Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan discusses the advances in HER2-targeted therapy for patients with HER2-expressing gastric cancer, including its use in combination with immune checkpoint blockade. Trastuzumab deruxtecan (known as T-DXd) is the first HER2-targeting antibody-drug conjugate that has demonstrated a better response rate and longer overall survival compared to standard chemotherapy treatment. T-DXd also has a manageable safety profile, although patient monitoring is still required. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
